Pharmacy Pearls: 2022 Diabetes Updates
February 17th, 2022 | Pharmacy Pearls•DiabetesIn this edition of Pharmacy Pearls, you will find a few key updates from the 2022 American Diabetes Association Standards of Medical Care in Diabetes. Most notably, metformin (while still a preferred first-line agent) is no longer a “must-try” option, and first-line treatment should be selected based on patient-specific factors. Additional treatment guidance for patients who have heart failure and/or diabetic kidney disease is included, as well as a brief review of Semglee-yfgn® and its unbranded generic insulin glargine-yfgn, which are the first interchangeable alternatives to Lantus®. These agents should allow for reduced cost to patients and the health care system.
As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.
Loading...
Reload document 
Open in new tab 
